RxDoctor Payments Data

Michael Steiner, MD

Ophthalmology · Burien, WANPI 1831255868

Payments from drug & device makers

$426in general payments, 2019–2025

Across 11 payments — averaging $38.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$138
  • Alcon$119
  • AbbVie$59
  • Carl Zeiss Meditec AG$39
  • Apellis Pharmaceuticals, Inc.$25
  • Carl Zeiss Meditec, Inc.$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$37087%
  • Gifts$5613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$426 in reported general payments places this provider in the 35th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$107,160
Medicare patients
202
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost42$17,693
Fluorometholone180$12,921
Tobramycin-DexamethasoneTobramycin/Dexamethasone106$5,319
Prednisolone Acetate146$4,964
Latanoprost325$4,748
SimbrinzaBrinzolamide/Brimonidine Tart12$2,491
Acetazolamide42$1,389
Pilocarpine Hcl20$1,234
Timolol Maleate103$1,169
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$942
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$890
Prednisone93$331
Ofloxacin18$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$59$17,69342 claims
AlconSimbrinza$119$2,49112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Burien

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →